clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Fractures, Open D005597 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Paronychia D010304 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Ecchymosis D004438 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Prurigo D011536 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Duodenitis D004382 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Ergotism D004881 4 associated lipids
Cysts D003560 4 associated lipids
Foot Diseases D005534 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Psittacosis D009956 4 associated lipids
Parotitis D010309 4 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Ustundag GH et al. The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. 2017 Can J Gastroenterol Hepatol pmid:28656129
Peng X et al. Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. 2017 Int J Med Sci pmid:28638276
Ozturk O et al. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. 2017 Arab J Gastroenterol pmid:28601610
Aguilera-Correa JJ et al. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. 2017 Diagn. Microbiol. Infect. Dis. pmid:27863951
Alirezaei A et al. Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. 2017 Iran J Kidney Dis pmid:28575885
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Angol DC et al. from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. 2017 Biomed Res Int pmid:28555193
Ivanová L et al. Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. 2017 Environ. Res. pmid:28183039
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
El Haj C et al. The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? 2017 Med. Microbiol. Immunol. pmid:27639707
Jia L et al. Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. 2017 Bioorg. Med. Chem. Lett. pmid:28711353
Seyama S et al. Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). 2017 J. Antimicrob. Chemother. pmid:27999037
Zerbetto De Palma G et al. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. 2017 Microb. Drug Resist. pmid:27391421
Legendre T et al. [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. 2017 Encephale pmid:27178256
Choi HS et al. Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. 2017 Jpn. J. Infect. Dis. pmid:27169951
Serrano CA et al. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. 2017 J. Pediatr. Gastroenterol. Nutr. pmid:27159208
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Kim SY et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. 2017 Helicobacter pmid:28940815
Mukherjee D et al. Vancomycin and Clarithromycin Show Synergy against . 2017 Antimicrob. Agents Chemother. pmid:28923867
Koratala A et al. Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. 2017 Blood Purif. pmid:28268216
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Jung YS et al. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28776746
Makihara K et al. Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. 2017 Cancer Chemother. Pharmacol. pmid:28711984
Tanabe H et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. 2017 Dig. Dis. Sci. pmid:28664410
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Sue S et al. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. 2017 Intern. Med. pmid:28566587
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745
Zhang Z et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. 2017 Int. J. Antimicrob. Agents pmid:28188830
Huang CC et al. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. 2018 J Microbiol Immunol Infect pmid:28705770
Kabakambira JD et al. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial. 2018 BMC Gastroenterol pmid:30165823
Yotsu RR et al. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). 2018 Cochrane Database Syst Rev pmid:30136733
Tang D et al. [Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment]. 2018 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:30124214
Byeon JY et al. Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. 2018 Arch. Pharm. Res. pmid:30117082
Park CG et al. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: A prospective, observational study. 2018 Medicine (Baltimore) pmid:30113472
Morgene MF et al. HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. 2018 Virology pmid:30077071
Shinozaki S et al. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen. 2018 Kaohsiung J. Med. Sci. pmid:30041763
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Heffernan CB et al. Does Clarithromycin Cause Hearing Loss? A 12-Year Review of Clarithromycin Therapy for Nontuberculous Mycobacterial Lymphadenitis in Children. 2018 Ann. Otol. Rhinol. Laryngol. pmid:30032669
Hamza D et al. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance. 2018 Microb. Pathog. pmid:30031039
Vianna JS et al. The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori. 2018 Rev. Inst. Med. Trop. Sao Paulo pmid:29972462
Myojin S et al. Chronic otitis media caused by Mycobacterium abscessus spp. massiliense treated with tigecycline in a 10-year-old child. 2018 Int. J. Infect. Dis. pmid:29966711
Liou JM et al. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. 2018 Gastroenterology pmid:29964036
Kwofie SK et al. Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. 2018 Molecules pmid:29954088
Abu-Khalaf N et al. The Taste of Commercially Available Clarithromycin Oral Pharmaceutical Suspensions in the Palestinian Market: Electronic Tongue and In Vivo Evaluation. 2018 Sensors (Basel) pmid:29401675
Tanabe H et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29950163
Sandri A et al. Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. 2018 Virulence pmid:29938577
Gonzalez-Hormazabal P et al. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. 2018 BMC Gastroenterol pmid:29925321
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Rodríguez-Sevilla G et al. Influence of three-dimensional lung epithelial cells and interspecies interactions on antibiotic efficacy against Mycobacterium abscessus and Pseudomonas aeruginosa. 2018 Pathog Dis pmid:29648588
Namkoong H et al. Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia. 2018 PLoS Pathog. pmid:29621339
Berende A et al. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. 2018 PLoS ONE pmid:29608590
Mabe K et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. 2018 J. Infect. Chemother. pmid:29605555
Chen SA et al. HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients. 2018 Basic Clin. Pharmacol. Toxicol. pmid:29575644
van Dyk M et al. Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries. 2018 Eur. J. Clin. Pharmacol. pmid:29572563
Chen J et al. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene. 2018 Ann. Clin. Microbiol. Antimicrob. pmid:29562911
Rodríguez-Sevilla G et al. Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model. 2018 Int. J. Med. Microbiol. pmid:29555180
Leung WK et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. 2018 Gastroenterology pmid:29550592
Kusuki M et al. Determination of the antimicrobial susceptibility and molecular profile of clarithromycin resistance in the Mycobacterium abscessus complex in Japan by variable number tandem repeat analysis. 2018 Diagn. Microbiol. Infect. Dis. pmid:29550059
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Reisfeld L et al. Cutaneous mycobacteriosis in a captive Amazonian manatee Trichechus inunguis. 2018 Dis. Aquat. Org. pmid:29516862
Fiorini G et al. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. 2018 Eur J Gastroenterol Hepatol pmid:29481383
Talarico S et al. High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. 2018 Helicobacter pmid:29480566
Takemori N et al. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. 2018 J Med Case Rep pmid:29454372
Xu R et al. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. 2018 Eur. J. Clin. Pharmacol. pmid:29453492
Aderemi AO et al. Oxidative stress responses and cellular energy allocation changes in microalgae following exposure to widely used human antibiotics. 2018 Aquat. Toxicol. pmid:30125766
Sue S et al. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. 2018 Helicobacter pmid:29271026
Nakase K et al. Long-term administration of oral macrolides for acne treatment increases macrolide-resistant Propionibacterium acnes. 2018 J. Dermatol. pmid:29235673
Cho EH et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. 2018 J. Infect. Chemother. pmid:29223615
Compain F et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. 2018 Diagn. Microbiol. Infect. Dis. pmid:29217419
Li H et al. Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study. 2018 Scand. J. Gastroenterol. pmid:29214879
Jung JH et al. Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for Infection. 2018 Gut Liver pmid:29212313
Deng J et al. Lack of additional effects of long-term, low-dose clarithromycin combined treatment compared with topical steroids alone for chronic rhinosinusitis in China: a randomized, controlled trial. 2018 Int Forum Allergy Rhinol pmid:29195025
Beer-Davidson G et al. Detection of Helicobacter pylori in stool samples of young children using real-time polymerase chain reaction. 2018 Helicobacter pmid:29181860
Muñoz-Gómez P et al. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. 2018 Helicobacter pmid:29178562
Zagari RM et al. Treatment of Helicobacter pylori infection: A clinical practice update. 2018 Eur. J. Clin. Invest. pmid:29144559
Liu DS et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. 2018 Clin. Microbiol. Infect. pmid:29138101
Redondo JJ et al. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. 2018 Diagn. Microbiol. Infect. Dis. pmid:29111147
Iwamoto J et al. Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. 2018 Intern. Med. pmid:29093413
Inagaki Y et al. Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. 2018 Intern. Med. pmid:29093379
De Lorenzi G et al. Mycobacterium genavense Infection in a Domestic Ferret (Mustela putorius furo). 2018 Top Companion Anim Med pmid:30502861
McNicholl AG et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial. 2018 Helicobacter pmid:30141228
Silva GM et al. Helicobacter pylori antimicrobial resistance in a pediatric population. 2018 Helicobacter pmid:30091503
Popovic V et al. Mycobacterium shimoidei-cavitary pulmonary disease with favorable outcome. 2018 Folia Microbiol. (Praha) pmid:28913757
Mahachai V et al. Helicobacter pylori management in ASEAN: The Bangkok consensus report. 2018 J. Gastroenterol. Hepatol. pmid:28762251
Bilgilier C et al. Prospective multicentre clinical study on inter- and intrapatient genetic variability for antimicrobial resistance of Helicobacter pylori. 2018 Clin. Microbiol. Infect. pmid:28669844
Barros S et al. Cat Scratch Disease: Not a Benign Condition. 2018 Ocul. Immunol. Inflamm. pmid:28665750
Ullah S et al. Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability. 2018 Artif Cells Nanomed Biotechnol pmid:28541761
Yoshida S et al. Association between sequevar and antibiotic treatment outcome in patients with Mycobacterium abscessus complex infections in Japan. 2018 J. Med. Microbiol. pmid:29227218
Cheung KS et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for : a population-based study. 2018 Gut pmid:29089382
Choi IJ et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. 2018 N. Engl. J. Med. pmid:29562147
Ribaldone DG et al. Helicobacter pylori eradication: poor medical compliance from East to West of the world. 2018 Scand. J. Gastroenterol. pmid:29383955
Suzuki K et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. 2018 Respir Investig pmid:29325687